Back to products
Metabolic
New
Semaglutide
GLP-1 receptor agonist
$149
AUD · 5mg vial
99.2% purity
COA included
Lyophilised
In stock
A long-acting GLP-1 analogue studied for glycaemic control, appetite regulation, and weight management.
Research use only. Not for human consumption, diagnosis, or therapeutic use. For in-vitro and laboratory research purposes only.
- GLP-1 receptor agonism
- Studied for appetite regulation
- Supports glycaemic control research
- Extended half-life profile
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a modified backbone for extended half-life. It is widely studied for glycaemic control, satiety signalling, and body composition research.
Synthesised with high-fidelity solid-phase methods and confirmed by mass spectrometry.
